Why Genomic Testing Made A Difference For One Woman’s Breast Cancer

Why Genomic Testing Made A Difference For One Woman’s Breast Cancer

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed decisions about her disease journey.

Leveraging TAILORx Findings to Guide Testing and Treatment Decisions in Node-Negative Breast Cancer

Panelists discuss how the TAILORx trial data were transformative for estrogen receptor–positive breast cancer by establishing clearer thresholds for chemotherapy benefit, while raising important questions about whether younger patients with intermediate scores benefit from chemotherapy itself or from the ovarian suppression it causes.